Related Experiment Video
Updated: Mar 13, 2026
05:56
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
2.4K
Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting
1Cancer Care Program Central and South America, World Health Organization, Indiana University School of Medicine South Bend, Indiana, USA. rmnavari@gmail.com.
Drugs of Today (Barcelona, Spain : 1998)
|October 11, 2016
Summary
Chemotherapy-induced nausea and vomiting (CINV) management has improved with new antiemetics. This review details rolapitant, a newer NK1 receptor antagonist, comparing its efficacy against aprepitant and netupitant for CINV prevention.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Chemotherapy-induced nausea and vomiting (CINV) significantly impacts patient quality of life and treatment adherence.
- Recent advancements include 5-HT3 receptor antagonists, NK1 receptor antagonists, and olanzapine for CINV control.
- Aprepitant, the first NK1 receptor antagonist, was approved in 2003.
Purpose of the Study:
- To describe rolapitant, a selective NK1 receptor antagonist.
- To evaluate rolapitant's role in preventing CINV.
- To compare rolapitant with other NK1 receptor antagonists, aprepitant and netupitant.
Main Methods:
- Review of clinical data and FDA approvals for NK1 receptor antagonists.
- Comparative analysis of efficacy and safety profiles.
- Focus on rolapitant's pharmacological properties and clinical application.
Main Results:
- Rolapitant, approved in 2015, offers a new option for CINV prevention.
- NK1 receptor antagonists have significantly improved CINV management.
- Rolapitant provides an alternative to aprepitant and netupitant.
Conclusions:
- Rolapitant represents a valuable addition to the antiemetic armamentarium for CINV.
- Understanding the differences between NK1 receptor antagonists is crucial for optimal patient care.
- Continued research aims to further refine CINV prophylaxis strategies.
Keywords:
5-HT3 receptor antagonistsAntiemeticsAprepitantChemotherapy-induced nausea and vomitingNetupitantRolapitantMore Related Videos
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
715
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
715
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
763
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
763
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.0K
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
890
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
890
01:26Pharmaceutical Poisoning: Treatment Strategies
113
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
113
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K